Samsung Bioepis, Biogen Get European Commission Approval For Opuviz, A Biosimilar To Aflibercept
(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.
manilatimes1h
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's ...
manilatimes1h
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics entered into License, Research and Co-Development Agreement HCW Biologics to receive upfront payment of $7 ...
Yahoo Finance2h
How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...
ETF Daily News13h
Biogen (NASDAQ:BIIB) Price Target Raised to $300.00
Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...
ZNetwork on MSN22h
RFK Jr. Is a Whacked-Out Crank, but He Is Right About the Pharmaceutical Industry
RFK Jr.’s main claim to fame, apart from his ancestry, is from saying crazy things about vaccines. As has ...